Precision treatments company DalCor Pharmaceuticals revealed on Wednesday the addition of Fouzia Laghrissi-Thode to its board of directors.
Currently, Dr Laghrissi-Thode serves as vice-president at AstraZeneca, leading the US Renal-Cardiology Therapeutic Area based in San Francisco as well as led the Global Cardiovascular Metabolism Therapeutic Area.
Previously, Dr.Laghrissi-Thode has worked with Novartis, Sandoz and Roche in clinical development, global strategic marketing, business development and licensing in therapeutic areas including diabetes, renal and the central nervous system as well as engaged in the development of Dalcetrapib and the Dal-HEART programme at Roche.
Earlier in her career, Dr Laghrissi-Thode was a board member of the Healthcare Businesswomen's Association (HBA) Europe and was recognized by HBA in 2012 for her work in developing and promoting women leadership in healthcare.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials